ViGenCell Inc.
Financials
Valuation Metrics
ViGenCell Inc.'s Market Cap is ₩959B. At end of 2025 it was ₩1999B. Ranked #1241 of 2,410 in KR market (top 51%), #673 of 1,631 on KOSDAQ (top 41%), #138 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 95.94B KRW | KR#1,241/2,410 Sec#138/231 |
| Revenue | 922.0M KRW | KR#2,377/2,410 Sec#219/231 |
| Net Income | -13.28B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 54.28B KRW | KR#2,166/2,410 Sec#194/231 |
| Net Assets | 43.72B KRW | KR#1,991/2,410 Sec#172/231 |
| Employees | 63 | KR#1,934/2,410 Sec#171/231 |
| Value | ||
| P/B | 2.19x | KR#2,028/2,410 Sec#155/231 |
| P/S | 104.05x | KR#2,384/2,410 Sec#212/231 |
| FCF Yield | -14.40% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -30.36% | KR#2,175/2,410 Sec#175/231 |
| ROA | -24.46% | KR#2,268/2,410 Sec#187/231 |
| Op. Margin | -1533.39% | KR#2,374/2,410 Sec#219/231 |
| Revenue Growth | 310.56% | KR#17/2,410 Sec#5/231 |
| Financial Health | ||
| Debt Ratio | 24.14% | KR#468/2,410 Sec#57/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -13.82B KRW | KR#1,795/2,410 Sec#165/231 |
| Cash | 3.93B KRW | KR#2,091/2,410 Sec#197/231 |
| Current Ratio | 15.27x | KR#44/2,410 Sec#15/231 |
| Performance | ||
| 1Y Return | 37.85% | KR#212/2,410 Sec#9/231 |
| 1M Return | -19.45% | KR#1,906/2,410 Sec#186/231 |
| From 52W High | -73.04% | KR#2,140/2,410 Sec#187/231 |
| 1Y MDD | -71.96% | KR#2,035/2,410 Sec#175/231 |
| Trading | ||
| Volume | 38,585 shares | KR#893/2,410 Sec#93/231 |
| Trading Value | 181.2M KRW | KR#1,027/2,410 Sec#112/231 |
| Foreign Own. | 2.04% | KR#1,607/2,410 Sec#156/231 |
| Per Share | ||
| EPS | -648 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,133 KRW | KR#2,052/2,410 Sec#170/231 |
Company Info
Established in 2013, the company is a bio venture specializing in pharmaceutical research and development and immune cell therapy development. Based on HLA research from The Catholic University of Korea College of Medicine, it develops immunotherapies using human blood-derived immune cells and is a cell therapy specialist with domestic clinical trial experience in antigen-specific killer T-cell research. Utilizing its ViTier platform technology, the company is developing treatments for NK/T-cell lymphoma and acute myeloid leukemia. Vaxcell-Bio was established in 2013 and is headquartered in Seoul-si, Geumcheon-gu.